Skip to main content
Premium Trial:

Request an Annual Quote

Shares in Ciphergen Rise 6.6 Percent on Breast Cancer Diagnostics News

NEW YORK, Dec. 9 (GenomeWeb News) - Shares in Ciphergen Biosystems were up 6.6 percent, or $.06, at $.97 in mid-afternoon trading one day after the company announced plans to develop breast cancer diagnostics.

 

As GenomeWeb News reported this morning, Ciphergen is developing diagnostics based on a "series of discoveries" that have been made using the company's SELDI technology.

 

Although no timeline was announced, the company expects to collaborate with the University of College London and UCL BioMedica, Ciphergen said.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.